Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
NCT00049127Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2003
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib in Oligodendroglioma (OG) and oligoastrocytoma (OA) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoints: 6-month Progression-free Survival, Maximum Tolerated Dose and 1 more. Started Jun 2003; status: completed.
02
Drugs
03
Conditions
Oligodendroglioma (OG)oligoastrocytoma (OA)
Beyond the preview
Go deeper on NCT00049127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049127.